COMP <GO>
REGN vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Regeneron Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: REGN 7
— JNJ 7
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: REGN
LAST: $927.89 (+13.33%) • MKT CAP: $84.30B
balance-sheet
7.72
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (REGN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | REGN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 25.50% | -16.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.2x | 18.5x | +1.70 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 5.14% | 2.97% | +2.17 | REGN | /fcf-yield <GO> |
| Operating Margin | 24.90% | 34.70% | -9.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 31.40% | 28.50% | +2.90 | REGN | /net-margins <GO> |
| Revenue Growth (YoY) | 1.00% | 6.00% | -5.00 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.44% | 0.00% | +0.44 | REGN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 7.72 | 5.59 | +2.13 | REGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.20% | +0.20 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 79.1 | 60.4 | +18.76 | REGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 1.08 | +0.08 | REGN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 23.0x | -5.60 | REGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $84.30B | $662.49B | -$578.20B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | REGN REV | JNJ REV | REGN GROSS % | JNJ GROSS % | REGN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.34B | $94.19B | 44.0% | 67.9% | $4.33B | $19.70B |
| FY 2024 | $14.20B | $88.82B | 44.0% | 69.1% | $3.78B | $19.84B |
| FY 2023 | $13.12B | $85.16B | 44.0% | 44.0% | $4.00B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
REGN // BETA 1.16
JNJ // BETA 1.08